Dimension Therapeutics Inc is a gene therapy platform company engaged in discovering and developing new therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations.
Company profile
Ticker
DMTX
Exchange
Website
CEO
Annalisa Jenkins
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
17 Nov 17
EFFECT
Notice of effectiveness
13 Nov 17
25-NSE
Exchange delisting
7 Nov 17
8-K
Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics
7 Nov 17
POS AM
Prospectus update (post-effective amendment)
7 Nov 17
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Nov 17
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Nov 17
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Nov 17
SC 14D9/A
Tender offer solicitation (amended)
7 Nov 17
SC TO-T/A
Third party tender offer statement (amended)
7 Nov 17
Latest ownership filings
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|